Healthcare Services company Suraksha Diagnostic announced Q2FY26 results Total Income: Rs 795.80 million against Rs 680.67 million during Q2FY25, change 16.9%. EBTIDA: Rs 249.66 million against Rs 245.07 million during Q2FY25, change 1.9%. EBTIDA Margin: 31.7% for Q2FY26. PAT: Rs 88.28 million against Rs 101.56 million during Q2FY25, change -13.1%. PAT Margin: 11.2% for Q2FY26. Ritu Mittal, Joint Managing Director & CEO, said: “Suraksha reported another quarter of strong top-line growth, driven primarily by test volumes. The QoQ andYoY total revenue growth was 8.3% and 16.9%, respectively. I am happy to announce that we have added 11 centres in H1FY26. We are working on 3 hub centres and 6spoke centres, which will be operational in the second half of FY26, which will take the total count to 20 for theyear. In Q1FY26, we launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and moleculartesting services. The lab is now fully operational and we expect to leverage the same to drive future growth. As the new centres mature, their margin contributions will increase, moving overall performance closer toindustry benchmarks and supporting improved profitability across our network. We remain committed to creating value for our shareholders, driven by innovation, operational excellence andsustainable growth.” Result PDF
Healthcare Services company Suraksha Diagnostic announced Q1FY26 results For Q1FY26, the company reported revenue from operations of Rs 725.86 million, reflecting a growth of 19.52% compared to Q1FY25. EBITDA for Q1FY26 reached Rs 246.56 million, marking a 13.51% increase from Q1FY25. EBITDA margin for Q1FY26 stood at 33.97%. PAT for Q1FY26 stood at Rs 91.75 million, reflecting a growth of 19.67% YoY. PAT margin for Q1FY26 was 12.64%. Ritu Mittal, Joint Managing Director & CEO said: “We are pleased to report a strong performance for Q1FY26, driven by consistent growth across our operations. In the quarter, we have also marked a major milestone with the launch of Suraksha Genomics, this new vertical, equipped with state-of-the-art high-throughput sequencing platforms, positions us at the forefront of precision medicine in Eastern India. Our strategic focus remains ambitious and future-ready. We are actively expanding into whole-genome and metagenomic testing, while integrating AI-assisted variant interpretation to elevate diagnostic accuracy. Additionally, we are laying the groundwork for population-scale genomic screening programs, an initiative that holds transformative potential for public health. Clinical partnerships continue to be a cornerstone of our approach, enabling us to translate scientific advancements into meaningful improvements in patient care and research outcomes. As newer centres stabilise and begin contributing significantly, we expect to see a stronger and more profitable financial profile across our network. We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics.” Result PDF
Healthcare Services company Suraksha Diagnostic announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: For Q4FY25, the company reported revenue from operations of Rs 651.0 million, reflecting a growth of 18.0% compared to the same quarter last year. EBITDA for Q4FY25 reached Rs 200.1 million compared to Rs 204.5 million in the previous year. The EBITDA margin for Q4FY25 stood at 30.7%. PAT for Q4FY25 stood at Rs 71.7 million, reflecting a growth of 13.4% year-on-year. The PAT margin for Q4FY25 was 11.0%, compared to 11.5% in the same quarter last year During the quarter ended 31 March 2025, the Company entered into a Share Subscription Agreement to acquire 95,841 equity shares of Rs10/- each in Fetomat Wellness Private Limited ("Fetomat"), representing a 16.17% stake, at Rs 100 lakhs. Subsequently, after 31 March 2025, the Company entered into Share Purchase Agreements with existing shareholders of Fetomat to acquire an additional 2,77,582 equity shares of Rs10/- each, increasing its total equity stake to approximately 63%, thereby obtaining control and making Fetomat a subsidiary of the Company FY25 Financial Highlights: For the year ended FY25, revenue amounted to Rs 2,520.9 million, a growth of 15.3 % year-on-year. For FY25, EBITDA totaled Rs 850.9 million, a growth of 15.6% year-on-year. The EBITDA margin for FY25 stood at 33.8%, up from 33.7% in the corresponding period. For FY25, PAT reached Rs 309.8 million, an increase of 34.0 % year-on-year. Added total of 7 Centers in the year with 1 big, 1 medium, 3 small centers and 2 PPP centers. Commenting on the results Ritu Mittal, Joint Managing Director & CEO said, - “We are pleased to present our first full-year financial results post-listing, marking a strong performance across FY25 with revenue growing by 15.3% year-on-year and PAT increasing by 34.0% year-on-year. During the year, we added 7 centers, despite diversions such as the management’s focus on the IPO, coupled with unfavorable events such as the doctors’ strike and the Bangladesh issue. Looking ahead, we are optimistic about expansion, with approvals already in place for the majority of our planned centers. We anticipate adding 15-18 centers in FY26, supporting our long-term growth trajectory. The acquisition of Fetomat Wellness Private Limited ('Fetomat’) in April 2025, marked our entry into the field of genomic medicine. Fetomat operates in the healthcare segment with a focus on pregnancy care, women’s ultrasound scanning, prenatal diagnostics, therapy, genetic counseling, and medical training for doctors. We believe this acquisition brings significant synergies with our existing operations and opens new avenues for sustainable growth. We expect our EBIDTA and PAT margins to improve further as we scale our operations and our centers reach maturity. With higher throughput, improved operating leverage and tighter cost controls, we expect meaningful margin expansion in our mature centers. As newer centers stabilize and start contributing significantly, we anticipate a stronger, more profitable financial profile across the network.” Result PDF
Healthcare Services company Suraksha Diagnostic announced Q3FY25 results For Q3FY25, the company reported revenue from operations of INR 595.1 million, reflecting a growth of 14.8% compared to Q3FY24. EBITDA for Q3FY25 reached INR 188.6 million, marking a 16.7% increase from Q3FY24.The EBITDA margin for Q3FY25 stood at 31.7%, up from 31.2% in the Q3FY24. PAT for Q3FY25 stood at INR 59.9 million, reflecting a growth of 31.9% YoY. The PAT margin for Q3FY25 was 10.1%, compared to 8.8% in the Q3FY24. Ritu Mittal, Joint Managing Director & CEO said: We reported strong performance during the third quarter and nine months ended FY25 and remain poised to continue to deliver strong revenue growth and margins over the long term. Given the expectations, our performance was curtailed in current quarter due to external factors such as the doctors’ strike, which had a lingering adverse impact on our operations during the quarter. The seasonal weakness during the third quarter reflected in a pull-back in our top-line and EBITDA levels, when comparing on a quarter-on-quarter basis. However, margins were partially supported on a YoY basis on the back of efficient cost control measures. We remain steadfast in our focus on internal growth through the addition of new centers as well as exploring inorganic growth opportunities. These focus areas position us well to further strengthen our dominance in the Eastern region of India. We expect to continue to leverage our strong presence to drive a pick-up in the business and margins going forward. Result PDF